Trump Administration reclassifies marijuana as Schedule III drug under federal law
Updated
Updated · The Wall Street Journal · Apr 26
Trump Administration reclassifies marijuana as Schedule III drug under federal law
8 articles · Updated · The Wall Street Journal · Apr 26
The Justice Department’s move allows licensed marijuana businesses to deduct expenses from taxes, affecting medical marijuana producers and retailers nationwide.
This reclassification signals government approval and may encourage pot shops to emphasize therapeutic benefits, amid concerns about marijuana’s impact on adolescent brain development and cognitive function.
Recent studies highlight increased teen cannabis use and associated health risks, while over two dozen states have legalized recreational marijuana and 40 permit medical use, reflecting ongoing national debate.
As cannabis gets a tax break, is new research on teen brain damage being ignored?
Can Medicare be forced to cover cannabis products not approved by the FDA?
Why does the government now say medical cannabis is safer than recreational pot?
Will this major policy shift finally lead to insurance coverage for medical cannabis?
With medical cannabis rescheduled, is full federal legalization now inevitable?
Could medical cannabis businesses receive massive federal tax refunds for past years?